Michael J. Morris, MD, discusses an ongoing phase I/IIa study looking at radium-223 with docetaxel in patients with bone metastasis from castration-resistant prostate cancer.
For more resources and information regarding targeted therapies in cancer: targetedhc.com/
- Dr. Morris on Radium-223 Plus Docetaxel in Patients With Bone Metastasis From CRPC ( Download)
- Dr. Antonarakis on Sipuleucel-T Plus Radium-223 in Bone-Metastatic CRPC ( Download)
- DORA trial: radium-223 plus docetaxel for mCRPC ( Download)
- Bone-migrated prostate cancer and Radium-223 therapy ( Download)
- Optimizing Therapy with Radium-223 for Prostate Cancer ( Download)
- Bone-Targeted Therapy for Prostate Cancer: Radium-223 ( Download)
- Radium-223 Alone and with Other Agents for Prostate Cancer ( Download)
- Dr. Daniel George on Radium-223 in Combinations for Metastatic Castration-Resistant Prostate Cancer ( Download)
- Radium-223 after abiraterone: symptomatic skeletal events in patients with mCRPC ( Download)
- Dr. Petrylak Discusses the Isotope Radium-223 ( Download)
- Radium-223 in men with bone mCRPC ( Download)
- Radium-223 Safety Prior to or After Chemotherapy ( Download)
- Should Radium 223 Be Given Earlier to Metastatic Prostate Cancer Patients ( Download)
- Radium-223 for bone predominant metastatic castration resistant prostate cancer ( Download)
- Dr. Daniel George on the Incorporation of Radium-223 in Advanced Prostate Cancer ( Download)
